Looking for a new broker?
Celcuity Inc. stock is up 38.35% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 December’s closed higher than November. 100% of analysts rate it a buy.
Celcuity Inc. focuses on the development of molecularly targeted therapies for cancer patients in the United States. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3k signaling activity in breast and ovarian tumor cells.
